Barclays’s Relmada Therapeutics RLMD Stock Holding History

Barclays’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,100	Closed	-$7.33K	–	5304
2022 Q4	$7.33K	Buy	+2,100	New	+$18.4K	﹤0.01%	4960

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's RLMD Position: Q2 2026 in Review

Barclays reduced its Relmada Therapeutics (RLMD) stake by 42% in Q2 2026, selling an estimated $264K and leaving 51,234 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #3392.

Barclays first reported a position in RLMD in Q1 2022 and has held it in 17 quarters since. The position peaked at $679K in Q1 2024. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Barclays held 51,234 shares of Relmada Therapeutics worth $355K as of Q2 2026.
Barclays sold 37,719 Relmada Therapeutics shares in Q2 2026, an estimated $264K.
Relmada Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3392 holding.
Barclays first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 17 quarters since.
Barclays's Relmada Therapeutics position peaked at $679K in Q1 2024.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.